Innate Pharma Stock Today
IPHYF Stock | USD 1.28 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 22
|
Innate Pharma is trading at 1.28 as of the 25th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 1.28. Innate Pharma has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Innate Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of May 2023 and ending today, the 25th of November 2024. Click here to learn more.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. The company has 80.21 M outstanding shares. More on Innate Pharma
Moving together with Innate Pink Sheet
0.62 | NVO | Novo Nordisk AS | PairCorr |
0.63 | NONOF | Novo Nordisk AS | PairCorr |
0.78 | CSLLY | CSL | PairCorr |
0.72 | CMXHF | CSL Limited | PairCorr |
0.7 | REGN | Regeneron Pharmaceuticals | PairCorr |
Moving against Innate Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Innate Pink Sheet Highlights
Chairman | Herve Brailly |
Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Innate Pharma [IPHYF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Small-Cap' category with a current market capitalization of 275.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Innate Pharma's market, we take the total number of its shares issued and multiply it by Innate Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Innate Pharma classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 80.21 M outstanding shares.
Innate Pharma has accumulated about 123.35 M in cash with (58.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Innate Pharma Probability Of Bankruptcy
Ownership AllocationInnate Pharma has a total of 80.21 Million outstanding shares. Innate Pharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Innate Ownership Details
Innate Pharma Risk Profiles
Mean Deviation | 1.4 | |||
Standard Deviation | 5.34 | |||
Variance | 28.49 | |||
Risk Adjusted Performance | (0.09) |
Innate Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Innate Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
All Next | Launch Module |
Innate Pharma Corporate Management
DVM MBA | VP Founder | Profile | |
Frederic MBA | VP CFO | Profile | |
Odile Belzunce | VP Operations | Profile | |
Mondher MD | Chairman CEO | Profile | |
Alessandro MD | Founder | Profile | |
Jean Fourni | Founder | Profile |
Additional Information and Resources on Investing in Innate Pink Sheet
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Innate Pink Sheet please use our How to Invest in Innate Pharma guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.